A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Launched by MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. · Mar 26, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called bulumtatug fuvedotin for patients with triple-negative breast cancer (TNBC) who have already received certain types of therapies. The purpose is to see if this drug can be effective for patients who have previously been treated with antibody-drug conjugates, which are special medicines that target cancer cells. The trial is currently not recruiting participants, but it aims to include adults aged 18 and older who have measurable cancer that meets specific guidelines.

To participate in this study, patients need to have recurrent or metastatic TNBC and must have received prior treatments with specific drugs. They should be in reasonably good health, able to provide consent, and willing to undergo certain procedures like blood transfusions if necessary. However, there are several conditions that would exclude someone from participating, such as having a recent serious infection, certain types of cancer treatment, or specific medical conditions that could affect safety. If patients join the trial, they can expect close monitoring and assessment of their health as they receive the study medication.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Patient has measurable disease by RECIST v1.1
• • Recurrent or metastatic triple-negative breast cancer patients as per current ASCO/CAP guidelines
• • Patient has received prior treatment with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload.
• • Patient has received no more than 3 prior lines of cytotoxic therapy in the locally advanced or metastatic setting.
• • Provision of archival tumor tissue or fresh tumor biopsy.
• • Capable of giving informed consent
• • Male or female subjects aged ≥ 18 years.
• • Subjects must be willing to receive blood transfusions if medically indicated.
• • ECOG 0-1
• • Adequate hematologic and organ function
• • Life expectancy of at least 3 months as assessed by the investigator
• • Compliance with contraceptive requirement
• Exclusion Criteria:
• • Have received any prior treatment with enfortumab vedotin, tisotumab vedotin or other MMAE based or nectin-4 targeted antibody-drug conjugates.
• • Unstable CNS metastasis requiring treatment in the last 28 days.
• • Acute infection requiring IV treatment in the last 14 days.
• • Grade ≥2 peripheral neuropathy.
• • Pregnant or breastfeeding women.
• • Life-threatening illness or uncontrolled medical conditions that could compromise the subject's safety or put the study outcomes at risk
• • Any systemic anticancer therapy in the last 28 days prior to first administration of study drug.
• • Active HCV, HBV or HIV infection unless well controlled with anti-viral therapy.
• • Active or chronic corneal disorder, keratitis, corneal ulcerations or Sjogren's syndrome.
• • Have any ongoing acute inflammatory skin disease or chronic skin disease not well controlled.
• • Have been diagnosed with another primary malignancy except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or subjects with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
• • Have significant, uncontrolled or active cardiovascular disease
• • Have active or a history of pneumonitis or interstitial lung disease that requires corticosteroid treatment. Patients with radiation pneumonitis that does not require treatment is allowed.
• • Have uncontrolled diabetes.
• • Have received any strong CYP3A4 inhibitors within 14 days prior to the first dose of study drug.
• • Subjects known to be hypersensitive to bulumtatug fuvedotin or to any components of the formulation.
• • History of drug abuse including narcotic and psychiatric drugs within 12 months prior to screening.
• • Have received a live vaccine within 30 days of planned start of study therapy.